BioSpace News Archive

Ocugen, Inc. today announced the appointment of Marna C. Whittington, PhD, to the Board of Directors. Her term became effective March 21, 2022.

Crescita Therapeutics Inc. today reported its financial results for the three months and fiscal year ended December 31, 2021 (“Q4-F2021” and “F2021”).

AccuStem Sciences, Inc., a life sciences company dedicated to improving outcomes for patients with cancer, is pleased to announce that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company in the United States.

Accordant announced today Pamela Ronka Maroulis , CFRE, (Pam) will serve as the new president of the health care management consulting firm. Accordant founder, Betsy Chapin Taylor, FAHP, will continue serving as the organization’s chief executive officer.

Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, is pleased to announce that the United States Patent and Trademark Office has granted a patent (US11278624) protecting novel formulations of the Group’s proprietary insulin products, AT247 and AT278.

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced the initiation of a Phase 1 study of RT-102, an oral formulation of the human parathyroid hormone analog PTH(1-34) for the treatment of osteoporosis, delivered via RaniPill™ capsule.

AIM ImmunoTech Inc., an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, announced Thomas Equels, Chief Executive Officer of AIM, will participate at the 2022 Virtual Growth Conference presented by Maxim Group LLC and hosted by M-Vest, taking place March 28-30, 2022.

Synthetic Biologics, Inc., a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, announced that Frank Tufaro, Ph.D., will transition from Chief Operating Officer of recently acquired VCN Biosciences to Chief Operating Officer of Synthetic Biologics.

BioSig Technologies, Inc. announced the completion of its previously announced underwritten public offering of 2,611,739 shares of its common stock, $0.001 par value per share, at a price to the public of $1.15 per share.

Inhibikase Therapeutics, Inc. announced that Dr. Milton Werner, Ph.D., the Company’s President & Chief Executive Officer will present in the Maxim Group 2022 Virtual Growth Conference, being held from March 28th through 30th.